These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 8504796)
41. Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: Trinka E; Rocamora R; Chaves J; Koepp MJ; Rüegg S; Holtkamp M; Moreira J; Fonseca MM; Castilla-Fernández G; Ikedo F Ther Adv Neurol Disord; 2023; 16():17562864231193530. PubMed ID: 37675038 [TBL] [Abstract][Full Text] [Related]
42. Carbamazepine plus stiripentol: is polytherapy by design possible? Lockard JS; Levy RH Epilepsia; 1988; 29(4):476-81. PubMed ID: 3391151 [TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates. Aldenkamp AP; Rentmeester T; Hulsman J; Majoie M; Doelman J; Diepman L; Schellekens A; Franken M; Olling M Eur J Clin Pharmacol; 1998 Apr; 54(2):185-92. PubMed ID: 9626926 [TBL] [Abstract][Full Text] [Related]
44. Comparative bioavailability of carbamazepine from two slow-release preparations. Reunanen M; Heinonen EH; Nyman L; Anttila M Epilepsy Res; 1992 Mar; 11(1):61-6. PubMed ID: 1563339 [TBL] [Abstract][Full Text] [Related]
45. Association of drug levels & pharmacokinetics of carbamazepine with seizure control. Vasudev A; Tripathi KD; Puri V Indian J Med Res; 2000 Dec; 112():218-23. PubMed ID: 11247200 [TBL] [Abstract][Full Text] [Related]
46. Lack of interaction of gabapentin with carbamazepine or valproate. Radulovic LL; Wilder BJ; Leppik IE; Bockbrader HN; Chang T; Posvar EL; Sedman AJ; Uthman BM; Erdman GR Epilepsia; 1994; 35(1):155-61. PubMed ID: 8112239 [TBL] [Abstract][Full Text] [Related]
47. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913 [TBL] [Abstract][Full Text] [Related]
48. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Mimrod D; Specchio LM; Britzi M; Perucca E; Specchio N; La Neve A; Soback S; Levy RH; Gatti G; Doose DR; Maryanoff BE; Bialer M Epilepsia; 2005 Jul; 46(7):1046-54. PubMed ID: 16026556 [TBL] [Abstract][Full Text] [Related]
49. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204 [TBL] [Abstract][Full Text] [Related]
50. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Miller AD; Krauss GL; Hamzeh FM Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458 [TBL] [Abstract][Full Text] [Related]
51. Comparison between the Cobas Integra immunoassay and high-performance liquid chromatography for therapeutic monitoring of carbamazepine. Hermida J; Bóveda MD; Vadillo FJ; Tutor JC Clin Biochem; 2002 May; 35(3):251-4. PubMed ID: 12074835 [TBL] [Abstract][Full Text] [Related]
52. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation. Reunanen M; Heinonen E; Anttila M; Järvensivu P; Lehto H; Hokkanen E Epilepsy Res; 1990 Jul; 6(2):126-33. PubMed ID: 2387286 [TBL] [Abstract][Full Text] [Related]
53. Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children. Paxton JW; Aman MG; Werry JS Epilepsia; 1983 Dec; 24(6):716-24. PubMed ID: 6641647 [TBL] [Abstract][Full Text] [Related]
54. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence. Korinthenberg R; Haug C; Hannak D Neuropediatrics; 1994 Aug; 25(4):214-6. PubMed ID: 7824094 [TBL] [Abstract][Full Text] [Related]
55. Acute oral loading of carbamazepine-CR and phenytoin in a double-blind randomized study of patients at risk of seizures. Van Der Meyden CH; Kruger AJ; Müller FO; Rabie W; Schall R Epilepsia; 1994; 35(1):189-94. PubMed ID: 8112244 [TBL] [Abstract][Full Text] [Related]
56. Carbamazepine drug interactions: the influence of concurrent drug therapy on serum concentrations of carbamazepine and its epoxide metabolite. Wang RB; Liu LT; Yiu CH; Chang TY Zhonghua Yi Xue Za Zhi (Taipei); 1990 Apr; 45(4):222-32. PubMed ID: 2168269 [TBL] [Abstract][Full Text] [Related]
57. Treatment of epilepsy in mentally retarded patients with a slow-release carbamazepine preparation. Kaski M; Heinonen E; Sivenius J; Tuominen J; Anttila M J Ment Defic Res; 1991 Jun; 35 ( Pt 3)():231-9. PubMed ID: 1920391 [TBL] [Abstract][Full Text] [Related]
58. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Hartley R; Forsythe WI; McLain B; Ng PC; Lucock MD Clin Pharmacokinet; 1991 Mar; 20(3):237-46. PubMed ID: 2025982 [TBL] [Abstract][Full Text] [Related]
59. The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. Cho YW; Kim DH; Motamedi GK Seizure; 2011 May; 20(4):336-9. PubMed ID: 21316267 [TBL] [Abstract][Full Text] [Related]
60. Clinical monitoring during carbamazepine slow-release, once-daily monotherapy. Stefan H; Schäfer H; Kuhnen C; Schneider S Epilepsia; 1988; 29(5):571-7. PubMed ID: 3137020 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]